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DIFFERENCE IN FREQUENCY OBSTETRIC FISTULA IN NIGERIAN  AND 
EUROPEAN WOMEN 
Ogbodo Amobichukwu Kingsley, Onwughara Obinna Prince - students of 3 course. 
Scientific supervisor – as. T.V.Kopytsja 
Sumy State University, Department of Obstetrics and Gynecology 
An obstetric fistula is an abnormal opening between the vagina and organs of pelvis.Each year, 
more than a quarter million women in Nigeria die in pregnancy and childbirth, of those that do not 
perish, suffer  from obstetric fistula (OF).OF caused by of obstructed labor, without timely medical 
intervention or Cesarean section. During this time, the soft tissues of the pelvis are compressed 
between the baby’s head and the mother’s pelvic bones. The lack of blood flow causes tissue to die, 
creating a hole between the mother’s vagina and organs of pelvis . 
Aim: to establish the disparity to development of OFin African countries with respect to their 
European counterparts. 
Aterials and methods: we did an epidemiological research in the Nigerian communities for 
the last 18 months (FMN, UNPF). Women between the ages of 15-40yrs were taken into account, in 
various communities sited in Nigeria and United nations population, from the time of pregnancy till 
postnatal period. 
Results: In Nigeria 1.5million women yearly going into childbirth resulting in 2,000,000 
accounted births yearly.10% of childbirth results in OF, 15.6 % cases treated immediatiatly,32% 
much later and wide majority not treated. According WHO is estimated that two million women suffer 
from OF globally. The cases of OF in Europe has drastically reduced since the beginning of 21 
century, with a thin population of  estimate of 2 in every 1000 births. 
Conclusion: Nigeria accounts for over 45% of world OF cases having a very high risk of 
prevalence, relating to poverty, early marriage, illiteracy, lack of quality maternal care, abortions, 
distance from health facility. European cases has become almost extinct due to improved health 
facility and high standard of living. 
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Objective: To present a basic clinical research based on current evidence about advanced 
treatment methods for vulvovaginal atrophy during menopause.And on principles of management of 
patients with vulvovaginal atrophy.Vulvovaginal atrophy (VVA) is a common and underreported 
condition associated with decreased estrogenization of the vaginal tissue. Symptoms include dryness, 
irritation, soreness, and dyspareunia with urinary frequency, urgency, and urge incontinence. It can 
occur at any time in a woman's life cycle, although more commonly in the postmenopausal phase, 
during which the prevalence is close to 50%. Clinical findings include the presence of pale and dry 
vulvovaginal mucosa with petechiae. Vaginal rugae disappear, and the cervix may become flush with 
the vaginal wall 
Materials and Methods: Ukrainian and foreign sources onprevalence, cytological method, pap 
smear, colposcopy method (before and after treatment), current management andtreatment of 
vulvovaginal atrophy were reviewed. We observed three groups of women, few premenopausal 
women with VVA, postmenopausal women and a control group. New treatment methods were 
identified and used on patients of different age groups,. For the treatment we used; hormonal therapy, 
laser therapy. 
Results: The present clinical guidelines give currentdata and information on aetiology, 
pathogenesis, clinical presentation, diagnosis, differential diagnosis and treatments of vulvovaginal 
atrophy in menopausal women.These treatment methods can be used for women who are diagnosed 
VVA. And after treatment the patients showed positive response.  
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Conclusion:Vulvovaginal atrophy is a common disorder in menopausal women, however 
vulvovaginal atrophy (VVA) is an underreported condition associated with decreased estrogenization 
of the vaginal tissue. The knowledge and awareness of current aspects of its diagnosis, treatment and 
prevention will be able to render timely aid to patients and to improve their quality of life. 
After using the above methods of diagnosis and treatment, it can be said that the use of hormonal 
therapy and laser therapy is effective and can be used on women of all ages.  
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The fertility of a couple depends upon several factors in both the male and female. Ovulation 
induction involves the use of medication to stimulate development of one or more mature follicles in 
the ovaries of women who have anovulation and infertility. Letrozole, an aromatase inhibitor, has 
been demonstrated to be effective as an ovulation induction and controlled ovarian hyperstimulation 
agent.  
Introduction. The drug works primarily by competitively inhibiting the binding of estradiol to 
its receptor in the hypothalamus, thereby releasing the hypothalamus from negative inhibition and 
allowing increased release of follicle stimulating hormonefrom the pituitary. 
Letrozolehad been used in anovulatory women with great success. The drug has side effects far 
milder and less frequentthan others. 
Materials and Methods. This study is a retrospective cohort analysis with data extracted from 
medical record. Logistic regression analysis were performed to determine the importance of each 
predictor variable and its covariates. Terms remained in the equation as significant if 𝑃<0.15. 
Results. A total of 866 treatment cycles utilized a five-day dose of letrozole. 33 were 
administered 5 mg daily, 80 - 7.5 mg daily, 18 - 10 mg daily, and 735-12.5 mg daily. The number of 
predicted ovulations was significantly less for doses of 7.5 mg/day or less compared to doses of 
10 mg/day or more (𝑃< 0.001). This remained true when the data were filtered to include only first 
cycles on a given dose (𝑃 = 0.033). No significant differences were seen for pregnancy rates among 
doses. 
Summary. Letrozole, used in doses greater than those commonly employed, can produce 
enhanced follicular growth without detrimental effects upon the endometrium. Further study is clearly 
needed, including estradiol and androgen levels. Randomized trials comparing high-dose to low-dose 
administration would help determine the optimal starting dose for this medication in varying 
diagnoses. 
  
